Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer.

We found that bemcentinib and cabozantinib enhanced the efficacy of both chemotherapeutics by significantly diminishing their IC 50 values, whereas combinations with NPS-1034 failed to reach statistical significance ( Fig. 4C ; Supplementary Fig.

also in 6,035 other papers